Dr Jonathan Goldman speaks to ecancer about the phase 2 DeLLphi-309 study, which he presented data from at WCLC 2026.

The study compared tarlatamab administered every 2 weeks, every 3 weeks, or every 4 weeks following a step up dose. Extended interval schedules demonstrated consistent clinical activity, although objective response rates were numerically lower than with the standard every 2 week regimen.

Dr Goldman covers the efficacy findings, including objective response and progression free survival, as well as the safety profile of the different dosing schedules.

He notes that cytokine release syndrome and ICANS were among the key adverse events observed, with most events being low grade.

Looking to the potential for changing clinical practice; moving from fortnightly to 3- or 4-weekly administration could reduce treatment visits for patients receiving tarlatamab. The study can be seen in the context of the broader effort to make bispecific T-cell engager therapy more convenient and sustainable.

Dr Goldman explores the potential role of extended interval dosing in the evolving treatment landscape for previously treated SCLC and how these findings could inform future tarlatamab treatment strategies.